Previous studies have shown that ACE2 attenuated the metastasis of lung cancer and that TMPRSS2 fusion gene may induce resistance to EGFR-TKI, a standard first-line therapy for advanced NSCLC patients harboring EGFR mutation (27, 28). This evidence concerns the gene TMPRSS2 and lung carcinoma.